BRD4 and melanoma: For example, a recent study (44) showed that secreted phosphoprotein 1 (SPP1) expression can be a melanoma driver, and BET inhibitor NHWD-870 targets the BRD4 subunit and suppresses SPP1 expression and ultimately melanoma progression via the non-canonical NF-κB/SPP1 pathway (44).